A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis.

[1]  E. R. Sutherland,et al.  Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial , 2016, The Lancet.

[2]  J. Krueger,et al.  Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. , 2016, The Journal of allergy and clinical immunology.

[3]  T. Honda,et al.  The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. , 2015, The Journal of allergy and clinical immunology.

[4]  K. Iwatsuki,et al.  Dexamethasone but not tacrolimus suppresses TNF-α-induced thymic stromal lymphopoietin expression in lesional keratinocytes of atopic dermatitis model. , 2015, Journal of dermatological science.

[5]  A. Paller,et al.  Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. , 2015, The Journal of allergy and clinical immunology.

[6]  P. Lio,et al.  Comparison of Dermatology and Allergy Guidelines for Atopic Dermatitis Management. , 2015, JAMA dermatology.

[7]  M. Suárez-Fariñas,et al.  Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. , 2015, The Journal of allergy and clinical immunology.

[8]  Mayte Suárez-Fariñas,et al.  RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. , 2015, The Journal of allergy and clinical immunology.

[9]  E. Guttman‐Yassky,et al.  Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics , 2015, Journal of clinical medicine.

[10]  M. Suárez-Fariñas,et al.  Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. , 2015, The Journal of allergy and clinical immunology.

[11]  J. Krueger,et al.  The translational revolution and use of biologics in patients with inflammatory skin diseases. , 2015, The Journal of allergy and clinical immunology.

[12]  T. Litman,et al.  Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. , 2015, The Journal of allergy and clinical immunology.

[13]  G. Yancopoulos,et al.  Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[14]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. , 2014, Journal of the American Academy of Dermatology.

[15]  D. Leung,et al.  Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. , 2014, The Journal of allergy and clinical immunology.

[16]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[17]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. , 2014, Journal of the American Academy of Dermatology.

[18]  J. Krueger,et al.  Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. , 2014, The journal of allergy and clinical immunology. In practice.

[19]  M. Suárez-Fariñas,et al.  Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. , 2014, The Journal of allergy and clinical immunology.

[20]  Sara Harcharik,et al.  Steroid-sparing properties of emollients in dermatology. , 2014, Skin therapy letter.

[21]  R. Fölster-Holst,et al.  Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial. , 2013, Acta dermato-venereologica.

[22]  M. Suárez-Fariñas,et al.  Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.

[23]  M. Suárez-Fariñas,et al.  Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.

[24]  M. Akiyama,et al.  A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. , 2012, Journal of dermatological science.

[25]  M. Weichenthal,et al.  Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis , 2012, Allergy.

[26]  A. Bowcock,et al.  Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. , 2011, The Journal of allergy and clinical immunology.

[27]  K. Barnes,et al.  Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response. , 2011, The Journal of allergy and clinical immunology.

[28]  A. Bowcock,et al.  Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. , 2011, The Journal of allergy and clinical immunology.

[29]  K. Chapman,et al.  The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights , 2011, Molecular and Cellular Endocrinology.

[30]  Mayte Suárez-Fariñas,et al.  Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA) , 2010, PloS one.

[31]  M. Weichenthal,et al.  Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. , 2009, The Journal of allergy and clinical immunology.

[32]  J. Carucci,et al.  Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. , 2007, The Journal of allergy and clinical immunology.

[33]  P. J. Barnes,et al.  Corticosteroid effects on cell signalling , 2006, European Respiratory Journal.

[34]  R. Schwartz,et al.  Adverse effects of topical glucocorticosteroids. , 2006, Journal of the American Academy of Dermatology.

[35]  Mayte Suárez-Fariñas,et al.  Harshlight: a "corrective make-up" program for microarray chips , 2005, BMC Bioinformatics.

[36]  D. Norris.  Mechanisms of action of topical therapies and the rationale for combination therapy. , 2005, Journal of the American Academy of Dermatology.

[37]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[38]  W. Hoetzenecker,et al.  Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. , 2004, The Journal of investigative dermatology.

[39]  M. Mommaas,et al.  Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. , 2002, The Journal of investigative dermatology.

[40]  N. Pimpinelli,et al.  New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. , 2002, American journal of clinical dermatology.

[41]  M. Tomic-Canic,et al.  Keratins and the keratinocyte activation cycle. , 2001, The Journal of investigative dermatology.

[42]  G. Singh,et al.  Tachyphylaxis to Topical Steroid Measured by Histamine‐induced Wheal Suppression , 1986, International journal of dermatology.